Phase II study of Taxotere in advanced or/and metastatic breast cancer as a first or second line of treatment

被引：0
|
作者：
Borisova, TA [1 ]
Orel, NF [1 ]
Pirogova, NA [1 ]
Gorbounova, VA [1 ]
机构：
[1] Canc Res Canc, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
132
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [1] A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
    Martina Baur
    Allan T. van Oosterom
    Véronique Diéras
    Michele Tubiana-Hulin
    R. Charles Coombes
    Thomas Hatschek
    Michael Murawsky
    May Klink-Alakl
    Marcus Hudec
    Christian Dittrich
    [J]. Journal of Cancer Research and Clinical Oncology, 2008, 134 : 125 - 135
  • [2] A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
    Baur, Martina
    van Oosterom, Allan T.
    Dieras, Veronique
    Tubiana-Hulin, Michele
    Coombes, R. Charles
    Hatschek, Thomas
    Murawsky, Michael
    Klink-Alakl, May
    Hudec, Marcus
    Dittrich, Christian
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (02) : 125 - 135
  • [3] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Borner, MM
    Dietrich, D
    Stupp, R
    Moran, R
    Honegger, H
    Wernli, M
    Herrmann, R
    Pestalozzi, BC
    Saletti, P
    Hanselmann, S
    Müller, S
    Brauchli, P
    Castiglione-Gertsch, M
    Goldhirsch, A
    Roth, AD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1759 - 1766
  • [4] Taxotere® (T) and doxorubicin (D) combination:: A phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC)
    Vallejos, C
    Nunez, P
    Orlandi, L
    Carranza, H
    Fodor, M
    Reyes, JM
    Majlis, A
    Gavilanes, P
    Boussard, B
    Salas, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S329 - S329
  • [5] A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer:: a GINECO study
    Diéras, V
    Guastalla, JP
    Ferrero, JM
    Curé, H
    Weber, B
    Winckel, P
    Lortholary, A
    Mayer, F
    Paraiso, D
    Magherini, E
    Pujade-Lauraine, E
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (06) : 489 - 495
  • [6] Phase II study with Docetaxel (Taxotere) as second line treatment of advanced soft tissues sarcomas in adult
    Verusio, C
    Romanini, A
    Frustaci, S
    Comandone, A
    DeToma, D
    Dogliotti, L
    Piolini, M
    Lionetto, R
    Dani, C
    Santoro, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 507 - 507
  • [7] A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study
    Véronique Diéras
    Jean Paul Guastalla
    Jean Marc Ferrero
    Hervé Curé
    Béatrice Weber
    Philippe Winckel
    Alain Lortholary
    Françoise Mayer
    Désiré Paraiso
    Emmanuelle Magherini
    Eric Pujade-Lauraine
    [J]. Cancer Chemotherapy and Pharmacology, 2004, 53 : 489 - 495
  • [8] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    [J]. ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
  • [9] Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer
    Robert, N. J.
    Conkling, P. R.
    Kuefler, P. R.
    McIntyre, K. J.
    Zhan, F.
    Asmar, L.
    Wang, Y.
    Shonukan, O. O.
    O'Shaughnessy, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Epirubicin (EPI) and Taxotere (TXT) as first line chemotherapy in advanced breast cancer: A phase I study
    Michelotti, A
    Venturini, M
    Papaldo, P
    Donati, S
    Del Mastro, L
    Garrone, O
    Bergaglio, M
    Lionetto, R
    Guelfi, M
    Sguotti, C
    Cognetti, F
    Rosso, R
    Conte, PF
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 18 - 18
12345